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Abstract 
Lung cancer is a global healthcare concern 
with a low 5-year survival rate and a high 
proportion of advanced-stage cases at diagnosis. In 
the absence of distant metastasis, the most 
important prognostic marker is mediastinal lymph 
node involvement. Timely diagnosis and staging 
improves prognosis, making rapid, safe, and 
accurate investigation essential. 
Endoscopic bronchial ultrasound (EBUS) is a 
minimally invasive technique which allows for 
ultrasound-guided transbronchial needle aspiration 
(TBNA) during bronchoscopy, with cytological 
sampling of several intrathoracic groups of lymph 
nodes. EBUS reduces need for open surgical 
biopsy, with good sensitivity and specificity and 
excellent safety profile. 
This article reviews current evidence regarding use 
of EBUS in lung cancer staging, including its role 
in other intrathoracic malignancies. 
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Introduction 
Despite advances made in oncology and 
aggressive anti-smoking public health campaigns, 
lung cancer remains a significant burden in terms of 
patient morbidity and mortality. 2012 saw an 
estimated 1.6 million deaths worldwide from the 
disease, and incidence is increasing, with a 
projected 3 million fatalities predicted in 2035, 
mainly in the developing world.1 Especially of 
concern is the fact that average 5-year survival for 
all kinds of lung cancer is as low as 10-20%, with 
little variation in prognosis between developed and 
developing regions.2 The local data is similarly 
bleak: incidence of lung cancer in Malta is on the 
rise, especially in women – and it is associated with 
an even more worrying increase in mortality.3 
Lung cancer can be divided into small cell and 
non-small cell lung cancer, the former accounting 
for around 20% of cases and carrying a worse 
prognosis due to its usual late stage and 
inoperability on diagnosis.4 Comparatively, 48% of 
non-small cell lung cancer patients in the UK have 
stage IV disease on diagnosis,5 but keeping in mind 
that early stage I disease has a 72.5% 1-year 
survival rate, the importance of rapid diagnosis and 
staging is highlighted. 
The most widespread staging classification in 
use for lung cancer is the TNM staging system, 
shown in table 1.6 Nodal status is the most 
important prognostic marker in the absence of 
metastatic disease, as only patients with N0, N1 and 
very selected cases of N2 disease are amenable to 
surgery, which is the definitive curative treatment.7 
If surgery is not an option, patients should be 
referred for chemotherapy, radiotherapy, or a 
combination, with the intent of cure or palliation.8 
Thus, accurate nodal staging is crucial to guide the 
best possible selection of treatment.  
Conventional staging of lung cancer had so far 
included the use of CT, PET-CT, radiology-guided 
transthoracic biopsy and flexible bronchoscopy to 
determine extent of disease. Some centres offer 
mediastinoscopy under general anaesthesia. This is 
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available in the Maltese healthcare system, but is 
falling out of favour due to its invasive nature. 
However, there is significant delay, unnecessary 
investigation, and cost burden associated with 
multiple tests,9 and this creates a niche for an 
investigation that can provide extensive information 
at one go. Since its introduction in 1992, 
endoscopic bronchial ultrasound (EBUS) has 
become increasingly useful in this regard, providing 
excellent information with regard to both diagnosis 
and staging of lung cancer in one procedure. This 
year marks the introduction of EBUS in the Maltese 
healthcare system, with expected benefits in 
investigation of malignant and benign conditions 
alike. 
 
Table 1: TNM staging (Adapted from TNM7 staging system6) 
 
Primary tumour (T) 
TX Primary tumour cannot be assessed, or the tumour is proven by the presence of malignant cells 
in sputum or bronchial washing but is not visualised by imaging or bronchoscopy 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour ≤ 3cm in greatest dimension, surrounded by lung or visceral pleura, no bronchoscopic 
evidence of invasion more proximal than the lobar bronchus (not in the main bronchus) 
T1a Tumour ≤ 2 cm in greatest dimension 
T1b Tumour > 2 cm but ≤ 3 cm in greatest dimension 
T2 Tumour > 3 cm but ≤ 7 cm or tumour with any of the following: 
- Invades visceral pleura 
- Involves the main bronchus ≥ 2 cm distal to the carina 
- Associated with atelectasis/obstructive pneumonitis extending to hilar region but not 
involving the entire lung 
T2a Tumour > 3 cm but ≤ 5 cm in greatest dimension 
T2b Tumour > 5 cm but ≤ 7 cm in greatest dimension 
T3 Tumour > 7 cm or one that directly invades any of the following: chest wall (including 
superior sulcus tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, 
parietal pleura 
Or tumour in the main bronchus < 2 cm distal to the carina but without involvement of the 
carina 
Or associated atelectasis/obstructive pneumonitis of the entire lung or separate tumour 
nodule(s) in the same lobe. 
T4 Tumour of any size that invades any of the following: mediastinum, heart, great vessels, 
trachea, recurrent laryngeal nerve, oesophagus, vertebral body, or carina; or separate tumour 
nodule(s) in a different ipsilateral lobe 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional node metastasis 
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary 
nodes, including involvement by direct extension 
N2 Metastasis in the ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 Metastasis in the contralateral mediastinal, contralateral hilar, ipsilateral or contralateral 
scalene, or supraclavicular lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Separate tumour nodule(s) in contralateral lobe; tumour with pleural nodules or malignant 
pleural/pericardial effusion 
M1b Distant metastasis 
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Endoscopic bronchial ultrasound 
EBUS allows for real-time visualisation of the 
bronchi, mediastinum, and lung parenchyma using 
an ultrasound probe attachment during flexible 
fibreoptic bronchoscopy. The concept of concurrent 
endoscopy and ultrasonography is not limited to 
bronchoscopy; the use of endoscopic ultrasound 
(EUS) for the gastrointestinal tract is established 
and has also been introduced in Malta.10 Together, 
these two counterparts provide access to good-
quality imaging and biopsy of mediastinal lymph 
nodes previously only achievable with invasive 
surgical staging.  
There are a large variety of EBUS probes 
available on the market, but these can be broadly 
classified into radial probes (RP-EBUS) and convex 
probes (CP-EBUS). Radial probe EBUS has the 
advantage of higher-resolution (20-30MHz) 
circumferential imaging with better distal access. 
On the other hand one cannot perform real time 
ultrasound during biopsy using this technique.11 
Conversely, CP-EBUS (figure 2) is a larger, lower-
frequency 7.5MHz probe with better interventional 
utility, as transbronchial needle aspirations (TBNA) 
can be carried out with concurrent ultrasound 
guidance, improving safety profile and diagnostic 
yield compared to blind TBNA.12  
 
Figure 2: Convex-probe EBUS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Convex-probe EBUS-TBNA technique 
EBUS is carried out as a day procedure under 
conscious sedation or general anaesthesia. 
Contraindications to the procedure are few and 
similar to those of conventional bronchoscopy, 
summarised in table 2. Because of a theoretical risk 
of bleeding during TBNA, the current practice is to 
withhold antiplatelet agents and anticoagulants prior 
to the procedure.13 By convention, aspirin and 
warfarin are stopped for three days pre-procedure, 
with bridging heparin for warfarinised patients for 
whom omission of warfarin is contraindicated, and 
clopidogrel is stopped one week prior.  
 
Table 2: Contraindications to EBUS-TBNA 
Contraindications to EBUS-TBNA 
Current or recent myocardial ischaemia 
Severe hypoxaemia 
Haemodynamic instability 
Severe pulmonary hypertension 
Poorly-controlled heart failure 
COPD/asthma exacerbation 
Life-threatening dysrhythmias 
Patient on anticoagulation/antiplatelets (not stopped) 
Clotting abnormalities 
Intolerance to sedation/anaesthesia 
 
During the procedure, potentially malignant 
lymph nodes can be identified by the following 
characteristics: round shape, heterogeneous 
echogenicity, distinct margin, presence of 
coagulation necrosis sign (a hypoechoic area within 
an enlarged node showing absence of Doppler 
signal).14 Absence of all four features carries a 96% 
chance that the visualised node is benign. Once a 
potentially abnormal node is identified, this may be 
biopsied with a retractable 21 or 22 gauge needle 
introduced through the bronchoscope. The needle is 
then used to puncture the bronchial wall and pierce 
the suspicious node under ultrasound guidance. 
Suction is applied to obtain a cytology specimen, 
with at least three punctures per lymph node 
recommended to maximise yield,15 following which 
the needle is retracted. The procedure can be 
repeated for other abnormal nodes as needed.11 
The specimen obtained from EBUS-TBNA is 
a cytology specimen, which is handled in liquid 
fixative like conventional TBNA or transthoracic 
needle biopsy samples. In order to maximise tissue 
yield, manufacturers are developing new needles for 
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use in difficult-to-diagnose pathology such as 
lymphomas or rare cancers.16 Despite the current 
unavailability of histology specimens from EBUS-
TBNA, much information can be obtained from 
good-quality samples. A retrospective, multicentre 
study of 774 patients showed that 90% of EBUS-
TBNA samples were suitable for endothelial growth 
factor receptor (EGFR) testing and 77% were 
sufficient for subtyping with staining and 
immunohistochemistry.17  
Some specialised centres also offer rapid on-
site evaluation (ROSE) for EBUS-TBNA 
specimens, with review of samples during the 
procedure for e. While there are no current clinical 
trials available, several smaller-scale studies have 
reported that ROSE increases diagnostic yield in a 
cost-effective manner, with less strain on the 
pathology service due to insufficient samples.18-20 
Examination of lymphadenopathy during 
EBUS requires a good working knowledge of the 
anatomy of cervical and intrathoracic lymph nodes. 
The current convention is the International 
Association for Study of Lung Cancer (IASLC) 
lymph node map, published in 2014,21 seen in 
figure 1. The system describes 14 lymph node 
groups, or stations in the neck and chest, 
categorised into 7 zones, which may be involved in 
local and regional spread of lung cancer.  
 
Figure 1: Reproduced from IASLC mediastinal lymph node map21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is important to note that, while EBUS 
provides excellent access to certain lymph node 
stations, it is not technically possible to gain access 
to all of them, and other techniques such as EUS 
may be required to access lower thoracic stations. 
Table 3 summarises lymph node stations accessible 
to different investigation modalities.22  
Keeping in mind that different procedures 
access different nodes, there is an increasing 
question as to whether EBUS and EUS should be 
performed together in order to maximise accuracy 
and completeness of staging. A 2015 meta-analysis 
of 10 studies with 1080 participants showed that 
combination EUS and EBUS showed a significantly 
higher sensitivity for staging of lung cancer of 91% 
compared to 80% in EBUS alone, without 
significant increase in complication rate.23,24 
 However, this raises some concern as to 
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whether such extensive investigation is necessary in 
all cases. A 2010 US study used software models to 
compare cost-effectiveness between combined 
EUS-EBUS and EUS alone and reported that 
combining the two procedures is more cost-
effective in cases where there are enlarged 
mediastinal lymph nodes on CT, while absence of 
lymphadenopathy favours the use of EUS alone.25  
 
 
Table 3: Access to lymph node stations by procedure22 
Station EBUS EUS Mediastinoscopy Video-assisted 
thoracoscopic 
surgery 
(VATS)a 
1 – Low cervical, supraclavicular, sternal notch *  *  
2 – Upper paratracheal  * * *  
3 – Prevascular, retrotracheal * *  * 
4 – Lower paratracheal * * * * 
5 – Subaortic  * * b  
6 – Para-aortic  * c * b  
7 – Subcarinal * d * e * * 
8 – Para-oesophageal  *  * 
9 – Pulmonary ligament  *  * 
10 – Hilar *   * 
11 – Interlobar *    
12 – Lobar *    
13 – Segmental     
14 – Subsegmental     
a Unilateral access only 
b Extended mediastinscopy only 
c Requires trans-aortic biopsy 
d Anterior subcarinal nodes 
e Posterior subcarinal nodes 
 
Which investigations to use for staging? 
The 2014 Scottish Intercollegiate Guidelines 
Network (SIGN) guidelines for management of 
lung cancer states that a CT scan of the thorax and 
abdomen should be requested in patients with 
suspected lung cancer regardless of chest X-ray 
result. Chest CT is regarded as being positive for 
mediastinal lymphadenopathy with nodal size 
>10mm short axis diameter. However, the guideline 
acknowledges the high false positive and negative 
rates for diagnosing abnormal nodes on CT (45 and 
13% respectively)26 and recommends use of PET-
CT scan in patients being staged before radical 
treatment, which has the benefit of a low false 
negative rate of 5%.26 Patients with >10mm nodes 
on CT and/or positive uptake of FDG on PET 
should be considered for mediastinal nodal 
sampling for definitive staging, as combined PET 
and CT have sensitivity of 61% and specificity of 
96% for positive mediastinal nodes.27 The guideline 
recommends the use of EBUS-FNA with or without 
EUS-FNA for endoscopic assessment of suspected 
mediastinal involvement prior to 
mediastinoscopy.26 
Prior to EBUS gaining popularity, surgical 
staging with mediastinoscopy was regarded as the 
gold standard investigation of possible metastatic 
mediastinal lymphadenopathy, but this is 
changing.28,29 This day procedure involves the 
insertion of a rigid mediastinoscope through the 
suprasternal notch under general anaesthesia, with 
direct visualisation of the upper mediastinum and 
biopsy of abnormal tissue. However, increasing 
evidence backs the use of endosonography prior to 
invasive surgical staging, and one of the most 
important contributions is the 2010 ASTER trial. 
This shows that combination EUS/EBUS, followed 
by surgical staging if negative, prevents 
unnecessary thoracotomy in 1 in 7 patients 
compared to immediate surgical staging, with 
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similar sensitivities between the two arms (85% in 
endosonography versus 79% in mediastinoscopy) 
and reduced risk of complications in the 
endosonography (1% versus 6% in mediastinoscopy 
group).30 
These findings, coupled with the fact that 
combined EBUS and EUS are still more cost-
effective than mediastinoscopy,25 would lead one to 
believe that mediastinoscopy has no further role in 
staging of lung cancer. However, there is much 
controversy about the value of a negative EBUS, 
with varying negative predictive values available in 
the literature, especially for central tumours.31-33 
The present consensus is that mediastinoscopy 
should be considered in cases of negative EBUS, 
but is not an essential step prior to proceeding to 
thoracotomy; further research is needed to clarify 
mediastinoscopy’s role in modern lung cancer 
staging.  
Perhaps one of the greatest endorsements for 
EBUS has been the 2015 BOOST trial comparing 
standard staging investigations, as would be seen in 
a non-endosonography centre (such CT, PET-CT, 
conventional bronchoscopy, mediastinoscopy, CT-
guided biopsy), with the use of EBUS or EUS 
immediately following CT. The use of 
endosonography as an initial investigation was 
shown to reduce time from first outpatient contact 
to treatment decision by multidisciplinary team 
from 29 days to 14, and the EBUS/EUS group was 
noted to have a lower mean number of 
investigations per patient, unnecessary 
thoracotomies, and PET-CT scans. Both groups had 
the same number of patients being treated with 
curative intent, but EBUS was shown to be faster, 
less costly, and – following a post-hoc analysis of 
patient survival – associated with better post-
operative survival compared to patients staged 
conventionally.17 
 
EBUS in small-cell lung cancer 
Most studies on EBUS discuss its use in 
NSCLC due to its better amenability to surgery, but 
the limited data available on small-cell lung cancer 
appears promising. In a retrospective analysis of 
161 patients, use of EBUS for suspected SCLC 
showed sensitivity and specificity of 97.4% and 
100% respectively, with a negative predictive value 
of 60%34, echoing the findings of similar 
retrospective studies.35,36 However, the fact that 
SCLC is often non-resectable at diagnosis often 
precludes the use of EBUS for workup, making its 
role not as well-defined as in other tumours.  
 
EBUS in lymphoma 
The role of EBUS in lymphoma is highly 
controversial and guidelines do not currently 
recommend its use in suspected lymphoma cases.37 
Extensive data is limited but there is concern about 
high false negative rates, especially in Hodgkin’s 
lymphoma.38  Sensitivity data is variable but values 
range from 38%39 to 86.7%.40 Much of the problem 
centres around the fact that accurate diagnosis and 
subtyping of lymphoma requires histological 
samples, ideally with excisional biopsy.41 In fact, 
the use of ROSE is thought to be beneficial to 
improve diagnostic yield in lymphoma.42 There is 
also a large variability in the design and selection of 
patients studied, with recurrent cases often being 
grouped with suspected lymphoma patients, making 
meta-analysis difficult to design.  
 
EBUS in metastatic extrathoracic disease 
EBUS may also be an option for investigation 
of mediastinal lymphadenopathy in the context of 
extrathoracic malignancies.  A 2014 meta-analysis 
of 533 patients showed that pooled EBUS-TBNA 
sensitivity and specificity were 85% and 99% 
respectively, indicating diagnostic accuracy similar 
to that in NSCLC.34 Furthermore, EBUS is capable 
of delivering samples sufficient for 
immunohistochemistry and molecular analysis in 
around 80% of cases.43 
 
Conclusion 
Although there are still gaps in available 
evidence, the use of EBUS, with or without EUS, 
for mediastinal lymph node staging is safe, fast, 
accurate, and cost-effective.  EBUS shortens the 
time to diagnosis whilst ensuring that patients are 
staged accurately and referred for the appropriate 
treatment. Large-scale trials are needed to confirm 
the usefulness of EBUS in small-cell lung cancer 
and metastatic extrathoracic malignancy, but the 
future for this investigative modality appears bright. 
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